NCT02386800 2026-03-16CINC424A2X01B Rollover ProtocolNovartisPhase 4 Active not recruiting279 enrolled
NCT01787487 2025-10-09Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative NeoplasmM.D. Anderson Cancer CenterPhase 2 Active not recruiting121 enrolled
NCT04817007 2025-09-10A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)Bristol-Myers SquibbPhase 1/2 Active not recruiting216 enrolled
NCT04454658 2025-07-16Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With MyelofibrosisAbbViePhase 1 Active not recruiting21 enrolled
NCT04041050 2025-02-14A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative NeoplasmAbbViePhase 1 Active not recruiting85 enrolled